In This Article:
Acrivon Therapeutics ACRV is a precision oncology company that has seen significant progress across its proprietary Acrivon Predictive Precision Proteomics (AP3) platform in 2024.
Acrivon Therapeutics achieved statistically significant prospective validation of its AP3 patient selection approach via its ACR-368 OncoSignature assay. This assay demonstrated an ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy.
Its lead pipeline candidate, ACR-368/prexasertib, a CHK1/2 inhibitor, is being developed in phase II studies across multiple tumor types. In April, the company reported initial positive clinical data from a phase II study of ACR-368 for patients with locally advanced or metastatic, recurrent platinum-resistant ovarian cancer or endometrial adenocarcinoma. The study demonstrated an initial combined overall confirmed response rate of 50%, exceeding the clinical bar, which the company thinks is required to improve over standard of care.
Acrivon Therapeutics’ stock has risen 61.6% year to date against a decrease of 9.3% for the industry.
Image Source: Zacks Investment Research
Another candidate, ACR-2316, a WEE1/PKMYT1 inhibitor, has been designed for superior single-agent activity. In preclinical studies, the candidate showed superior activity versus benchmark WEE1 and PKMYT1 single-target inhibitors in multiple cancer models. Clinical studies on the candidate are expected to begin in the fourth quarter of 2024.
Acrivon Therapeutics carries a Zacks Rank #2 (Buy) currently. The Zacks Consensus Estimate for 2024 loss has narrowed from $2.98 per share to $2.47 per share over the past 60 days. For 2025, the loss estimate has narrowed from $2.88 per share to $2.55 per share over the same timeframe.
ACRV beat estimates in three of the trailing four quarters and missed the mark once, delivering an average earnings surprise of 3.56%.
Acrivon Therapeutics, Inc. Price and Consensus
Acrivon Therapeutics, Inc. price-consensus-chart | Acrivon Therapeutics, Inc. Quote
Other Stocks to Consider
Some other top-ranked stocks in the healthcare sector are Heron Therapeutics HRTX, Bioventus BVS and PMV Pharmaceuticals PMVP. While Bioventus has a Zacks Rank #1, Heron Therapeutics and PMV Pharmaceuticals have a Zacks Rank of 2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, 2024 estimates for Bioventus have improved from 16 cents per share to 27 cents per share. For 2025, earnings estimates have improved from 40 cents to 43 cents per share in the past 60 days. So far this year, shares of BVS are up 20.9%.